These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

79 related items for PubMed ID: 11019449

  • 1. Management trends. Resting energy expenditure in the HAART era.
    Shevitz AH.
    AIDS Read; 2000 Sep; 10(9):539-44; quiz 557-8. PubMed ID: 11019449
    [Abstract] [Full Text] [Related]

  • 2. Nutrition in the era of highly active antiretroviral therapy.
    Shevitz AH, Knox TA.
    Clin Infect Dis; 2001 Jun 15; 32(12):1769-75. PubMed ID: 11360219
    [Abstract] [Full Text] [Related]

  • 3. Dysregulated energy expenditure in HIV-infected patients: a mechanistic review.
    Chang E, Sekhar R, Patel S, Balasubramanyam A.
    Clin Infect Dis; 2007 Jun 01; 44(11):1509-17. PubMed ID: 17479951
    [Abstract] [Full Text] [Related]

  • 4. Increased resting energy expenditure, fat oxidation, and food intake in patients with highly active antiretroviral therapy-associated lipodystrophy.
    Sutinen J, Yki-Järvinen H.
    Am J Physiol Endocrinol Metab; 2007 Mar 01; 292(3):E687-92. PubMed ID: 17062843
    [Abstract] [Full Text] [Related]

  • 5. Understanding the role of HIV load in determining weight change in the era of highly active antiretroviral therapy.
    Mwamburi DM, Wilson IB, Jacobson DL, Spiegelman D, Gorbach SL, Knox TA, Wanke CA.
    Clin Infect Dis; 2005 Jan 01; 40(1):167-73. PubMed ID: 15614708
    [Abstract] [Full Text] [Related]

  • 6. Energy expenditure and wasting in human immunodeficiency virus infection.
    Macallan DC, Noble C, Baldwin C, Jebb SA, Prentice AM, Coward WA, Sawyer MB, McManus TJ, Griffin GE.
    N Engl J Med; 1995 Jul 13; 333(2):83-8. PubMed ID: 7777033
    [Abstract] [Full Text] [Related]

  • 7. Role of cytokines and testosterone in regulating lean body mass and resting energy expenditure in HIV-infected men.
    Roubenoff R, Grinspoon S, Skolnik PR, Tchetgen E, Abad L, Spiegelman D, Knox T, Gorbach S.
    Am J Physiol Endocrinol Metab; 2002 Jul 13; 283(1):E138-45. PubMed ID: 12067854
    [Abstract] [Full Text] [Related]

  • 8. Prevalence and predictors of HIV-associated weight loss in the era of highly active antiretroviral therapy.
    Batterham MJ, Garsia R, Greenop P.
    Int J STD AIDS; 2002 Nov 13; 13(11):744-7. PubMed ID: 12437893
    [Abstract] [Full Text] [Related]

  • 9. Calculating energy requirements for men with HIV/AIDS in the era of highly active antiretroviral therapy.
    Batterham MJ, Morgan-Jones J, Greenop P, Garsia R, Gold J, Caterson I.
    Eur J Clin Nutr; 2003 Feb 13; 57(2):209-17. PubMed ID: 12571651
    [Abstract] [Full Text] [Related]

  • 10. Short-term energy restriction reduces resting energy expenditure in patients with HIV lipodystrophy and hypermetabolism.
    Kosmiski LA, Bessesen DH, Stotz SA, Koeppe JR, Horton TJ.
    Metabolism; 2007 Feb 13; 56(2):289-95. PubMed ID: 17224345
    [Abstract] [Full Text] [Related]

  • 11. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
    Pozio E.
    Parassitologia; 2004 Jun 13; 46(1-2):89-93. PubMed ID: 15305694
    [Abstract] [Full Text] [Related]

  • 12. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K.
    Verh K Acad Geneeskd Belg; 2001 Jun 13; 63(5):447-73. PubMed ID: 11813503
    [Abstract] [Full Text] [Related]

  • 13. Energy expenditure and protein metabolism in human immunodeficiency virus infection and cancer cachexia.
    Mulligan K, Bloch AS.
    Semin Oncol; 1998 Apr 13; 25(2 Suppl 6):82-91. PubMed ID: 9625389
    [Abstract] [Full Text] [Related]

  • 14. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL.
    APMIS Suppl; 2003 Apr 13; (114):1-37. PubMed ID: 14626050
    [Abstract] [Full Text] [Related]

  • 15. Impact of depression on HIV outcomes in the HAART era.
    Hartzell JD, Janke IE, Weintrob AC.
    J Antimicrob Chemother; 2008 Aug 13; 62(2):246-55. PubMed ID: 18456650
    [Abstract] [Full Text] [Related]

  • 16. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY, Terrin N, Wanke C, Skinner S, Tchetgen E, Shevitz AH.
    Clin Infect Dis; 2005 Dec 01; 41(11):1662-70. PubMed ID: 16267741
    [Abstract] [Full Text] [Related]

  • 17. Body shape and composition in HIV-infected women: an urban cohort.
    Karmon SL, Moore RD, Dobs AS, Keruly J, Barnett S, Cofrancesco J.
    HIV Med; 2005 Jul 01; 6(4):245-52. PubMed ID: 16011529
    [Abstract] [Full Text] [Related]

  • 18. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy.
    European Collaborative Study.
    Clin Infect Dis; 2005 Feb 01; 40(3):458-65. PubMed ID: 15668871
    [Abstract] [Full Text] [Related]

  • 19. Metabolic consequences and therapeutic options in highly active antiretroviral therapy in human immunodeficiency virus-1 infection.
    Samaras K.
    J Antimicrob Chemother; 2008 Feb 01; 61(2):238-45. PubMed ID: 18070830
    [Abstract] [Full Text] [Related]

  • 20. Important differences in components of the metabolic syndrome between HIV-patients with and without highly active antiretroviral therapy and healthy controls.
    Bergersen BM, Schumacher A, Sandvik L, Bruun JN, Birkeland K.
    Scand J Infect Dis; 2006 Feb 01; 38(8):682-9. PubMed ID: 16857615
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.